European Commission and national competition authorities are pushing back against abuse of dominance in the pharmaceutical sector and high medicine prices
On 10 February 2021 the European Commission accepted commitments offered by pharmaceutical producer Aspen for price reductions for 6 critical cancer medicines. This brought an end to the Commission’s investigation under Article 102 TFEU (abuse of a dominant position) into Aspen’s pricing practices, which it had started in 2017. The investigation concerned Aspen’s pricing policy for its medicines, which are used in the treatment of certain types of cancer such as leukaemia and other haematological cancers.
Recent Dutch case law on the termination of agreements without cause
As part of transactions, parties often enter into term sheets and various types of ancillary agreements, such as consultancy or management agreements. Disputes concerning...Read more
COVID-19 and Dutch filing and accounting obligations
Earlier, at the end of last year, on LinkedIn we posted the legal alert below regarding director’s liability in bankruptcy pursuant to section 2:138/248 of the...Read more
Deliveroo drivers are employees
In February 2018, Deliveroo altered the relationship with its drivers in the Netherlands from an employment contract into a so-called partner agreement. However, less...Read more
Is exhaustion of trademark rights a matter of fact or a matter of intention?
The French company Moet Hennessy has lodged an appeal before the Netherlands Supreme Court against a decision of the court of appeal of The Hague to the effect that Moet...Read more
Every advantage has its disadvantage (and Vice Versa)
The General Court handed down a judgement in 2020 in which it annulled the Commission’s Decision regarding State aid granted to Valencia Club de Fútbol...Read more